{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:02:21Z","timestamp":1768417341292,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010316","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000}}],"reference-count":54,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010316.pub2","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T16:32:07Z","timestamp":1484325127000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["First-line combination therapy versus first-line monotherapy for primary hypertension"],"prefix":"10.1002","author":[{"given":"Javier","family":"Garj\u00f3n","sequence":"first","affiliation":[{"name":"Navarre Health Service; Drug Prescribing Service; Plaza de la Paz s\/n 4\u00aa Pamplona Navarra Spain 31002"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Carlos","family":"Saiz","sequence":"additional","affiliation":[{"name":"Navarre Health Service; Drug Prescribing Service; Plaza de la Paz s\/n 4\u00aa Pamplona Navarra Spain 31002"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Azparren","sequence":"additional","affiliation":[{"name":"Navarre Health Service; Drug Prescribing Service; Plaza de la Paz s\/n 4\u00aa Pamplona Navarra Spain 31002"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 J","family":"Elizondo","sequence":"additional","affiliation":[{"name":"Navarre Health Service; Pharmacy B, CHN; Irunlarrea 4 Pamplona Navarra Spain 31008"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idoia","family":"Gaminde","sequence":"additional","affiliation":[{"name":"Department of Health; Continuous Education and Research; Pabell\u00f3n de Docencia Recinto Hospital de Navarra Pamplona Spain 31008"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Jos\u00e9","family":"Ariz","sequence":"additional","affiliation":[{"name":"Navarre Health Service; Medical Practice; C\/San Martin de Unx 11- Tafalla Navarra Spain 31300"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Erviti","sequence":"additional","affiliation":[{"name":"Navarre Health Service; Drug Prescribing Service; Plaza de la Paz s\/n 4\u00aa Pamplona Navarra Spain 31002"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD010316.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0197-2456(03)00028-X","article-title":"The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics","volume":"24","author":"BENEDICT Group","year":"2003","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/HJH.0b013e32834069bd","article-title":"Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial","volume":"29","author":"Ruggenenti","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"19","key":"10.1002\/14651858.CD010316.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010316.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1161\/01.HYP.0000064943.51878.58","article-title":"Effect of low-dose perindopril\/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER","volume":"41","author":"Mogensen","year":"2003","journal-title":"Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD010316.pub2-BIB0005|cit5","first-page":"S15","article-title":"Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination","volume":"19","author":"Asmar","year":"2001","journal-title":"Journal of Hypertension. Supplement"},{"issue":"4","key":"10.1002\/14651858.CD010316.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1161\/hy1001.095774","article-title":"Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril\/indapamide combination in hypertensive patient: a comparison with atenolol","volume":"38","author":"Asmar","year":"2001","journal-title":"Hypertension"},{"issue":"1","key":"10.1002\/14651858.CD010316.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2003.07.039","article-title":"Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril\/indapamide in hypertensive subjects: comparison with atenolol","volume":"43","author":"London","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD010316.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.amjhyper.2003.11.001","article-title":"Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril\/indapamide first-line combination in hypertensive patients: the REASON study","volume":"17","author":"Mallion","year":"2004","journal-title":"American Journal of Hypertension"},{"issue":"9762","key":"10.1002\/14651858.CD010316.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","article-title":"Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial","volume":"377","author":"Brown","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/HJH.0b013e32834069bd","article-title":"Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial","volume":"29","author":"Ruggenenti","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD010316.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.111.174474","article-title":"Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) randomized clinical trial","volume":"58","author":"Ruggenenti","year":"2011","journal-title":"Hypertension"},{"issue":"6824","key":"10.1002\/14651858.CD010316.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical Research Council trial of treatment of hypertension in older adults: principal results","volume":"304","author":"MRC Working Party","year":"1992","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"15","key":"10.1002\/14651858.CD010316.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD010316.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/01.hjh.0000187253.35245.dc","article-title":"Perindopril\/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study","volume":"23","author":"Dahlof","year":"2005","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD010316.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/08037050903497238","article-title":"Combination therapy with angiotensin-converting enzyme inhibitors and indapamide impairs glucose tolerance in Chinese hypertensive patients","volume":"19","author":"Zhang","year":"2010","journal-title":"Blood Pressure"},{"issue":"5","key":"10.1002\/14651858.CD010316.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/10641963.2012.721841","article-title":"Olmesartan\/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients","volume":"35","author":"Derosa","year":"2013","journal-title":"Clinical and Experimental Hypertension"},{"issue":"6","key":"10.1002\/14651858.CD010316.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jash.2014.03.329","article-title":"Enalapril\/lercanidipine combination on markers of cardiovascular risk: a randomized study","volume":"8","author":"Derosa","year":"2014","journal-title":"Journal of the American Society of Hypertension"},{"issue":"9227","key":"10.1002\/14651858.CD010316.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1745-6215-12-53","article-title":"A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial","volume":"12","author":"Fuchs","year":"2011","journal-title":"Trials"},{"issue":"4","key":"10.1002\/14651858.CD010316.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/HJH.0000000000000837","article-title":"Effectiveness of chlorthalidone\/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial","volume":"34","author":"Fuchs","year":"2016","journal-title":"Journal of Hypertension"},{"issue":"20","key":"10.1002\/14651858.CD010316.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1002\/14651858.CD010316.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1002\/14651858.CD010316.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010316.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jash.2013.07.009","article-title":"Review of blood pressure control rates and outcomes","volume":"8","author":"Bakris","year":"2014","journal-title":"Journal of the American Society of Hypertension"},{"issue":"8","key":"10.1002\/14651858.CD010316.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003654.pub4","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","author":"Chen","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010316.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cjca.2015.02.016","article-title":"The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"31","author":"Daskalopoulou","year":"2015","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0027|cit27","unstructured":"European Medicines Agency Combined use of medicines affecting the renin- angiotensin system (RAS) to be restricted - CHMP endorses PRAC recommendation, 2014 www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2014\/05\/WC500167421.pdf"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0028|cit28","unstructured":"IECS (Institute of Clinical Effectiveness and Health Policy) EROS Early Review Organizing Software 2009"},{"issue":"28","key":"10.1002\/14651858.CD010316.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0030|cit30","unstructured":"US Drugs Food Administration ACE inhibitors: dual blockade of the RAS, 2014 www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm418829.htm"},{"issue":"2","key":"10.1002\/14651858.CD010316.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jash.2010.03.001","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"Journal of the American Society of Hypertension"},{"issue":"11","key":"10.1002\/14651858.CD010316.pub2-BIB0032|cit32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008167.pub3","article-title":"Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension","author":"Heran","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0033|cit33","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available fromhandbook.cochrane.org."},{"issue":"7","key":"10.1002\/14651858.CD010316.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.jhh.1000855","article-title":"Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation","volume":"13","author":"Hilleman","year":"1999","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0035|cit35","volume-title":"Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. ICH Harmonised Tripartite Guideline CPMP\/ICH\/377\/95","author":"International Conference on Harmonisation","year":"1995"},{"issue":"5","key":"10.1002\/14651858.CD010316.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"7404","key":"10.1002\/14651858.CD010316.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"31","key":"10.1002\/14651858.CD010316.pub2-BIB0038|cit38","first-page":"1","article-title":"Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy","volume":"7","author":"Law","year":"2003","journal-title":"Health Technology Assessment (Winchester, England)"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"7","key":"10.1002\/14651858.CD010316.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"e70111","DOI":"10.1371\/journal.pone.0070111","article-title":"Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1002\/14651858.CD010316.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MBP.0b013e32833a23d4","article-title":"Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials","volume":"15","author":"Lv","year":"2010","journal-title":"Blood Pressure Monitoring"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0042|cit42","first-page":"f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0043|cit43","volume-title":"Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update)","author":"National Collaborating Centre for Chronic Conditions","year":"2008"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0044|cit44","volume-title":"Hypertension: the Clinical Management of Primary Hypertension in Adults","author":"National Clinical Guideline Centre","year":"2011"},{"issue":"6","key":"10.1002\/14651858.CD010316.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamainternmed.2014.8012","article-title":"Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study","volume":"175","author":"Benetos","year":"2015","journal-title":"JAMA Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010316.pub2-BIB0046|cit46","first-page":"203","article-title":"I Brazilian position paper on antihypertensive drug combination","volume":"102","author":"Povoa","year":"2014","journal-title":"Arquivos Brasileiros de Cardiologia"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0047|cit47","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"7","key":"10.1002\/14651858.CD010316.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2165\/00003495-200161070-00004","article-title":"Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension","volume":"61","author":"Ruzicka","year":"2001","journal-title":"Drugs"},{"issue":"5","key":"10.1002\/14651858.CD010316.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","article-title":"Reducing inappropriate polypharmacy: the process of deprescribing","volume":"175","author":"Scott","year":"2015","journal-title":"JAMA Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD010316.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2146\/ajhp090419","article-title":"Combination therapy for the management of hypertension: a review of the evidence","volume":"67","author":"Sood","year":"2010","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD010316.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD010316.pub2-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Wiysonge CS Bradley HA Volmink J Mayosi BM Mbewu A Opie LH Beta-blockers for hypertension Cochrane Database of Systematic Reviews 2012 10.1002\/14651858.CD002003.pub4","DOI":"10.1002\/14651858.CD002003.pub4"},{"issue":"3","key":"10.1002\/14651858.CD010316.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001841.pub2","article-title":"First-line drugs for hypertension","author":"Wright","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010316.pub2-BIB0054|cit54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008170.pub2","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","author":"Xue","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010316.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010316.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:42:44Z","timestamp":1628548964000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010316.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hypertension Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":54,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010316.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD010316.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]}}}